Ametropia
Conditions
Brief summary
This is an unmasked, non-randomized, single arm, stratified, dispensing investigation of symptomatic and asymptomatic subject populations. Subjects will be assigned to a single study lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear for 1 week.
Interventions
Senofilcon A Daily Disposable Contact Lenses
Sponsors
Study design
Eligibility
Inclusion criteria
* Potential subjects must satisfy all of the following criteria to be enrolled in the study: 1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Between 18 and 55 (inclusive) years of age at the time of screening. 4. Be a current soft contact lens wearer in both eyes with a minimum of 3 days/week wear time over the last 1 month by self-report. 5. Have a baseline CLDEQ-8 score of either: 1. 7 or lower 2. 15 or greater 6. Subjects must possess a functional / usable pair of spectacles and bring them to the visit (only if applicable - to the investigators discretion). 7. Subjects must pass a pre-screening questionnaire. 8. Subjects must be willing to discontinue all contact lens wear for approximately 1 week/ 9. Subjects must present to visit 1 with their habitual lenses on eye for at least 6 hours.
Exclusion criteria
* Potential subjects who meet any of the following criteria will be excluded from participating in the study: 1. Currently pregnant or lactating, by self-report. 2. Any ocular or systemic allergies, disease or use of medication which may interfere with contact lens wear (at the discretion of the investigator). 3. Any active ocular abnormalities/conditions that may interfere with contact lens wear (at the discretion of the investigator). 4. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report. 5. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear. 6. Habitual contact lens wear modality as extended wear (≥1 night per month of extended wear). 7. Habitual contact lens is rigid gas permeable, toric, monovision or multi-focal 8. Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.) 9. Participation in any contact lens or lens care product clinical trial within 2 weeks prior to study enrollment. 10. Employee or employee's immediate family member of clinical site (e.g., Investigator, Coordinator, Technician). 11. Current habitual use of Restasis, Xiidra, ocular steroids, or any medication (RX or OTC) that may interfere with contact lens wear (at the discretion of the investigator).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Meibomian Gland Imaging | 4-Week Follow-up | Meibomian gland imaging was assessed in each each subject eye, at baseline, 4-Week Follow-up (during lens wear) and the the 5-Week Follow-up on subjects' bare eyes. Meibomian gland imaging is expressed interms of area of loss using the following grading scale: Degree 0 ≈ 0%; Degree 1 ≤ 25%; Degree 2 26% - 50%; Degree 3 51% - 75%; Degree 4 ≥ 75%. |
| Meibomian Gland Expressibility | 4-Week Follow-up | Meibomian glands were assessed in the three regions of each lower eyelid: temporal, central, and nasal. Approximately five glands are expressed per region with each use of the Meibomian Gland Evaluator. Secretions for each of the 5 glands selected within the three regions were graded using the following secretion grading scale: Grade 0 = No Secretion (Includes capped orifices), Grade 1 = Inspissated (semi-solid, toothpaste-like consistency), Grade 2 = Colored/Cloudy Liquid, Grade 3 = Clear Liquid Oil. The total grades for 5 glands per region was calculated for each subject. The total Meibomian Gland Secretion Score was calculated by adding the grades for the 15 glands assessed. Mean and standard deviation for total grade per region and total Meibomian Gland Secretion Score were reported for each stratum. Total scores range from 0 to 15 were lower score indicate worsening meibomian gland expressability. |
| Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings | 4-Week Follow-up | Lid margin evaluation was conducted for upper and lower lids for both left and right eyes. The presence of the following biomicroscopy findings were recorded as No/normal or Yes/abnormal: * Irregularity: Notching of Margin * Vascularity of Lid Margin: Telangiectasia * Meibomian Gland Pouting, Plugging, or Capping * Lid/Lash Margin Debris Findings. The number of positive findings (yes) was reported for each group. |
| Lid Wiper Epitheliopathy | 4-Week Follow-up | Horizontal length of staining and sagittal width of staining were graded for both upper and lower lids for each eye. Average grade was calculated separately for upper and lower lids, and the final grade was calculated as the average grade across upper and lower lids. Mean and standard deviation were reported for the final grade by stratum. Subjects were classified according to their final lid wiper epitheliopathy grade for each eye using the following scale: None = 0, Mild = 0.25 - 1.00, Moderate = 1.25 - 2.00, and Severe = 2.25 - 3.00. Final Grades range from 0 to 3, where higher final grades indicate worsening lid wiper epitheliopathy. |
| Conjunctival Folds | 4-Week Follow-up | Lid-parallel conjunctival folds (LIPCOF) will be evaluated in the area perpendicular to the temporal and nasal limbus on the bulbar conjunctiva above the lower lid (temporal and nasal LIPCOF, respectively), and classified using the LIPCOF grading scale: 0 = No conjunctival folds, 1 = One permanent and clear parallel fold, 2 = Two permanent and clear parallel folds (normally lower than 0.2mm), and 3 = More than two permanent and clear parallel folds (normally higher than 0.2mm). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Conjunctival Redness | 4-Week Follow-up | Limbal and bulbar conjunctival redness were assessed or each quadrant (nasal, temporal, inferior, superior) using the following scale: 0 = Normal, 1 = Trace, 2 = Mild, 3 = Moderate, and 4 = Severe. |
| Tear Film Lipid Pattern | 4-Week Follow-up | Tear film lipid pattern was recorded for each eye using the following categories: None, Open Meshwork, Closed (Tight Meshwork), Flow (Wave), Amorphous, Colors, and Other. |
| Conjunctival Staining | 4-Week Follow-up | Conjunctival staining was assessed for each eye by quadrant (Superior, Inferior, Nasal, Temporal) utilizing the following scale: Grade 0 = None (No conjunctival staining), Grade 1 = Trace (Scattered superficial punctate staining), Grade 2 = Mild (Regional or generalized punctate staining), Grade 3 = Moderate (Significant coalesced punctate staining), Grade 4 = Severe (Patch staining). |
| Corneal Staining | 4-Week Follow-up | Corneal staining was assessed for each eye by region (Central, Superior, Inferior, Nasal, Temporal). Corneal staining type was evaluated using the following the scale: Grade 0 = None, Grade 1 = Micropunctate, Grade 2 = Macropunctate, Grade 3 = Coalesced Macropunctate, and Grade 4 = Patch (\>1mm). Corneal staining area was evaluated using the following the scale: Grade 0 = 0% of region covered, Grade 1 = 10% of region covered, Grade 2 = 20% of region covered, Grade 3 = 30% of region covered, Grade 4 = 40% of region covered, Grade 5 = 50% of region covered, Grade 6 = 60% of region covered, Grade 7 = 70% of region covered, Grade 8 = 80% of region covered, Grade 9 = 90% of region covered, and Grade 10 = 100% of region covered. The following scale was used in the grading of corneal staining depth: Grade 0 = None, Grade 0 = Superficial epithelial, Grade 2 = Full epithelial, and Grade 3 = Stromal glow. |
| Tear Film Lipid Layer Thickness | 4-Week Follow-up | Tear film lipid layer thickness was measured for each eye using LipiView II. The Review Lipid Images screen provided numerical analysis of the measured lipid layer thickness in nanometers (nm) from 10 (thinnest) to 240 (thickest), with a precision of 1 nm and an accuracy of 10 nm. |
| Tear Film Stability | 4-Week Follow-up | Non-invasive tear break-up time (NIBUT) was measured for each eye to indicate the stability of the tear film. NIBUT is measured as the time interval in seconds after the final blink to the first appearance of distortion in the reflected rings; or to the time that the participant has to blink due to discomfort. Three measurements were taken on each eye. The average NIBUT was reported for each group. |
Countries
Canada, United States
Participant flow
Recruitment details
A total of 105 subjects were enrolled into this study. Of those enrolled 81, were dispensed a study lens while 24 subjects failed to meet all eligibility criteria. Of those dispensed a study lens, 73 completed the study while 8 subjects were discontinued. All subjects were disepsned the same study lens senofilcon A.
Pre-assignment details
Subjects were stratified into two subject groups: symptomatic (baseline CLDEQ-8 score of 15 or greater) and asymptomatic (baseline CLDEQ-8 score of 7 or lower).
Participants by arm
| Arm | Count |
|---|---|
| Asymptomatic Subjects with baseline CLDEQ-8 score of 7 or lower were assigned to the asymptomatic group throughout the entire duration of the study | 29 |
| Symptomatic Subjects with baseline CLDEQ-8 score of 15 or greater were assigned to the symptomatic group throughout the entire duration of the study. | 52 |
| Total | 81 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 2 | 2 |
| Overall Study | Discontinued as moving out of local area | 0 | 1 |
| Overall Study | Lost to Follow-up | 0 | 1 |
| Overall Study | Physician Decision | 1 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 1 |
Baseline characteristics
| Characteristic | Asymptomatic | Symptomatic | Total |
|---|---|---|---|
| Age, Continuous | 28.76 Years STANDARD_DEVIATION 7.229 | 28.17 Years STANDARD_DEVIATION 9.096 | 28.38 Years STANDARD_DEVIATION 8.4333 |
| Race/Ethnicity, Customized Asian | 7 Participants | 20 Participants | 27 Participants |
| Race/Ethnicity, Customized Black or African American | 1 Participants | 2 Participants | 3 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 3 Participants | 3 Participants |
| Race/Ethnicity, Customized White | 21 Participants | 27 Participants | 48 Participants |
| Region of Enrollment Canada | 18 Participants | 38 Participants | 56 Participants |
| Region of Enrollment United States | 11 Participants | 14 Participants | 25 Participants |
| Sex: Female, Male Female | 18 Participants | 36 Participants | 54 Participants |
| Sex: Female, Male Male | 11 Participants | 16 Participants | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 81 |
| other Total, other adverse events | 0 / 81 |
| serious Total, serious adverse events | 0 / 81 |
Outcome results
Conjunctival Folds
Lid-parallel conjunctival folds (LIPCOF) will be evaluated in the area perpendicular to the temporal and nasal limbus on the bulbar conjunctiva above the lower lid (temporal and nasal LIPCOF, respectively), and classified using the LIPCOF grading scale: 0 = No conjunctival folds, 1 = One permanent and clear parallel fold, 2 = Two permanent and clear parallel folds (normally lower than 0.2mm), and 3 = More than two permanent and clear parallel folds (normally higher than 0.2mm).
Time frame: 4-Week Follow-up
Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Asymptomatic | Conjunctival Folds | Temporal- Grade 0 | 27 eyes |
| Asymptomatic | Conjunctival Folds | Temporal- Grade 1 | 22 eyes |
| Asymptomatic | Conjunctival Folds | Temporal- Grade 2 | 3 eyes |
| Asymptomatic | Conjunctival Folds | Temporal- Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Folds | Nasal- Grade 0 | 43 eyes |
| Asymptomatic | Conjunctival Folds | Nasal- Grade 1 | 9 eyes |
| Asymptomatic | Conjunctival Folds | Nasal- Grade 2 | 0 eyes |
| Asymptomatic | Conjunctival Folds | Nasal- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Folds | Nasal- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Folds | Temporal- Grade 0 | 45 eyes |
| Symptomatic | Conjunctival Folds | Nasal- Grade 0 | 55 eyes |
| Symptomatic | Conjunctival Folds | Temporal- Grade 1 | 41 eyes |
| Symptomatic | Conjunctival Folds | Nasal- Grade 2 | 9 eyes |
| Symptomatic | Conjunctival Folds | Temporal- Grade 2 | 8 eyes |
| Symptomatic | Conjunctival Folds | Nasal- Grade 1 | 30 eyes |
| Symptomatic | Conjunctival Folds | Temporal- Grade 3 | 0 eyes |
Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings
Lid margin evaluation was conducted for upper and lower lids for both left and right eyes. The presence of the following biomicroscopy findings were recorded as No/normal or Yes/abnormal: * Irregularity: Notching of Margin * Vascularity of Lid Margin: Telangiectasia * Meibomian Gland Pouting, Plugging, or Capping * Lid/Lash Margin Debris Findings. The number of positive findings (yes) was reported for each group.
Time frame: 4-Week Follow-up
Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Asymptomatic | Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings | Irregularity: Notching of Margin | 1 Number of eyes |
| Asymptomatic | Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings | Vascularity of Lid Margin: Telangiectasia | 12 Number of eyes |
| Asymptomatic | Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings | Meibomian Gland Pouting, Plugging, or Capping | 12 Number of eyes |
| Asymptomatic | Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings | Lid/Lash Margin Debris Findings | 0 Number of eyes |
| Symptomatic | Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings | Lid/Lash Margin Debris Findings | 10 Number of eyes |
| Symptomatic | Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings | Irregularity: Notching of Margin | 5 Number of eyes |
| Symptomatic | Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings | Meibomian Gland Pouting, Plugging, or Capping | 33 Number of eyes |
| Symptomatic | Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings | Vascularity of Lid Margin: Telangiectasia | 21 Number of eyes |
Lid Wiper Epitheliopathy
Horizontal length of staining and sagittal width of staining were graded for both upper and lower lids for each eye. Average grade was calculated separately for upper and lower lids, and the final grade was calculated as the average grade across upper and lower lids. Mean and standard deviation were reported for the final grade by stratum. Subjects were classified according to their final lid wiper epitheliopathy grade for each eye using the following scale: None = 0, Mild = 0.25 - 1.00, Moderate = 1.25 - 2.00, and Severe = 2.25 - 3.00. Final Grades range from 0 to 3, where higher final grades indicate worsening lid wiper epitheliopathy.
Time frame: 4-Week Follow-up
Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Asymptomatic | Lid Wiper Epitheliopathy | 0.50 Units on a scale | Standard Deviation 0.718 |
| Symptomatic | Lid Wiper Epitheliopathy | 0.28 Units on a scale | Standard Deviation 0.489 |
Meibomian Gland Expressibility
Meibomian glands were assessed in the three regions of each lower eyelid: temporal, central, and nasal. Approximately five glands are expressed per region with each use of the Meibomian Gland Evaluator. Secretions for each of the 5 glands selected within the three regions were graded using the following secretion grading scale: Grade 0 = No Secretion (Includes capped orifices), Grade 1 = Inspissated (semi-solid, toothpaste-like consistency), Grade 2 = Colored/Cloudy Liquid, Grade 3 = Clear Liquid Oil. The total grades for 5 glands per region was calculated for each subject. The total Meibomian Gland Secretion Score was calculated by adding the grades for the 15 glands assessed. Mean and standard deviation for total grade per region and total Meibomian Gland Secretion Score were reported for each stratum. Total scores range from 0 to 15 were lower score indicate worsening meibomian gland expressability.
Time frame: 4-Week Follow-up
Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Asymptomatic | Meibomian Gland Expressibility | Central Lower Lid | 9.04 Score on a Scale | Standard Deviation 5.068 |
| Asymptomatic | Meibomian Gland Expressibility | Temporal Lower Lid | 8.71 Score on a Scale | Standard Deviation 4.795 |
| Asymptomatic | Meibomian Gland Expressibility | Nasal Lower Lid | 7.94 Score on a Scale | Standard Deviation 4.976 |
| Asymptomatic | Meibomian Gland Expressibility | Total Score | 25.69 Score on a Scale | Standard Deviation 13.964 |
| Symptomatic | Meibomian Gland Expressibility | Total Score | 22.55 Score on a Scale | Standard Deviation 12.649 |
| Symptomatic | Meibomian Gland Expressibility | Central Lower Lid | 8.07 Score on a Scale | Standard Deviation 5.055 |
| Symptomatic | Meibomian Gland Expressibility | Nasal Lower Lid | 6.54 Score on a Scale | Standard Deviation 4.571 |
| Symptomatic | Meibomian Gland Expressibility | Temporal Lower Lid | 7.94 Score on a Scale | Standard Deviation 4.803 |
Meibomian Gland Imaging
Meibomian gland imaging was assessed in each each subject eye, at baseline, 4-Week Follow-up (during lens wear) and the the 5-Week Follow-up on subjects' bare eyes. Meibomian gland imaging is expressed interms of area of loss using the following grading scale: Degree 0 ≈ 0%; Degree 1 ≤ 25%; Degree 2 26% - 50%; Degree 3 51% - 75%; Degree 4 ≥ 75%.
Time frame: 4-Week Follow-up
Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Asymptomatic | Meibomian Gland Imaging | Degree 0 | 10 eyes |
| Asymptomatic | Meibomian Gland Imaging | Degree 1 | 23 eyes |
| Asymptomatic | Meibomian Gland Imaging | Degree 2 | 18 eyes |
| Asymptomatic | Meibomian Gland Imaging | Degree 3 | 1 eyes |
| Symptomatic | Meibomian Gland Imaging | Degree 3 | 8 eyes |
| Symptomatic | Meibomian Gland Imaging | Degree 0 | 4 eyes |
| Symptomatic | Meibomian Gland Imaging | Degree 2 | 16 eyes |
| Symptomatic | Meibomian Gland Imaging | Degree 1 | 66 eyes |
Conjunctival Redness
Limbal and bulbar conjunctival redness were assessed or each quadrant (nasal, temporal, inferior, superior) using the following scale: 0 = Normal, 1 = Trace, 2 = Mild, 3 = Moderate, and 4 = Severe.
Time frame: 4-Week Follow-up
Population: All subjects dispensed a study lens.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Asymptomatic | Conjunctival Redness | Bulbar-Superior- Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Temporal- Grade 0 | 13 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Superior- Grade 4 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Inferior-Grade 2 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Nasal- Grade 0 | 26 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Nasal- Grade 0 | 12 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Nasal- Grade 1 | 25 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Nasal- Grade 2 | 3 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Temporal- Grade 1 | 37 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Nasal- Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Temporal- Grade 4 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Nasal- Grade 4 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Temporal- Grade 2 | 4 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Temporal- Grade 0 | 24 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Nasal- Grade 1 | 36 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Temporal- Grade 1 | 28 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Temporal- Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Temporal- Grade 2 | 2 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Inferior-Grade 4 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Temporal- Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Temporal- Grade 4 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Nasal- Grade 2 | 6 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Inferior- Grade 1 | 27 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Inferior-Grade 0 | 23 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Inferior- Grade 2 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Inferior- Grade 0 | 27 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Inferior- Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Nasal- Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Inferior- Grade 4 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Superior- Grade 0 | 23 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Superior- Grade 0 | 25 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Inferior-Grade 1 | 31 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Superior- Grade 1 | 29 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Superior- Grade 2 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Superior- Grade 1 | 30 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Superior- Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Nasal- Grade 4 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Limbal-Superior- Grade 4 | 0 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Superior- Grade 2 | 1 eyes |
| Asymptomatic | Conjunctival Redness | Bulbar-Inferior-Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Superior- Grade 1 | 45 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Inferior-Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Nasal- Grade 1 | 66 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Temporal- Grade 4 | 0 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Inferior-Grade 1 | 66 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Nasal- Grade 0 | 11 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Nasal- Grade 1 | 72 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Nasal- Grade 2 | 13 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Nasal- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Nasal- Grade 4 | 0 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Temporal- Grade 0 | 12 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Temporal- Grade 1 | 73 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Temporal- Grade 2 | 11 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Temporal- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Temporal- Grade 4 | 0 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Inferior-Grade 0 | 27 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Inferior-Grade 4 | 0 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Superior- Grade 0 | 31 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Superior- Grade 1 | 57 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Superior- Grade 2 | 8 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Superior- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Superior- Grade 4 | 0 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Nasal- Grade 0 | 28 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Nasal- Grade 2 | 2 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Nasal- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Nasal- Grade 4 | 0 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Temporal- Grade 0 | 33 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Temporal- Grade 1 | 58 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Temporal- Grade 2 | 5 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Temporal- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Inferior- Grade 0 | 40 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Inferior- Grade 1 | 55 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Inferior- Grade 2 | 1 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Inferior- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Inferior- Grade 4 | 0 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Superior- Grade 0 | 46 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Superior- Grade 2 | 5 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Superior- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Redness | Limbal-Superior- Grade 4 | 0 eyes |
| Symptomatic | Conjunctival Redness | Bulbar-Inferior-Grade 2 | 3 eyes |
Conjunctival Staining
Conjunctival staining was assessed for each eye by quadrant (Superior, Inferior, Nasal, Temporal) utilizing the following scale: Grade 0 = None (No conjunctival staining), Grade 1 = Trace (Scattered superficial punctate staining), Grade 2 = Mild (Regional or generalized punctate staining), Grade 3 = Moderate (Significant coalesced punctate staining), Grade 4 = Severe (Patch staining).
Time frame: 4-Week Follow-up
Population: All subjects dispensed a study lens.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Asymptomatic | Conjunctival Staining | Inferior-Grade 0 | 26 eyes |
| Asymptomatic | Conjunctival Staining | Temporal- Grade 0 | 20 eyes |
| Asymptomatic | Conjunctival Staining | Inferior-Grade 1 | 9 eyes |
| Asymptomatic | Conjunctival Staining | Nasal- Grade 2 | 19 eyes |
| Asymptomatic | Conjunctival Staining | Inferior-Grade 2 | 19 eyes |
| Asymptomatic | Conjunctival Staining | Temporal- Grade 1 | 19 eyes |
| Asymptomatic | Conjunctival Staining | Inferior-Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Staining | Nasal- Grade 0 | 17 eyes |
| Asymptomatic | Conjunctival Staining | Superior- Grade 0 | 28 eyes |
| Asymptomatic | Conjunctival Staining | Temporal- Grade 2 | 15 eyes |
| Asymptomatic | Conjunctival Staining | Superior- Grade 1 | 18 eyes |
| Asymptomatic | Conjunctival Staining | Nasal- Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Staining | Superior- Grade 2 | 8 eyes |
| Asymptomatic | Conjunctival Staining | Temporal- Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Staining | Superior- Grade 3 | 0 eyes |
| Asymptomatic | Conjunctival Staining | Nasal- Grade 1 | 18 eyes |
| Symptomatic | Conjunctival Staining | Superior- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Staining | Nasal- Grade 0 | 17 eyes |
| Symptomatic | Conjunctival Staining | Nasal- Grade 2 | 28 eyes |
| Symptomatic | Conjunctival Staining | Nasal- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Staining | Temporal- Grade 0 | 29 eyes |
| Symptomatic | Conjunctival Staining | Temporal- Grade 1 | 51 eyes |
| Symptomatic | Conjunctival Staining | Temporal- Grade 2 | 16 eyes |
| Symptomatic | Conjunctival Staining | Temporal- Grade 3 | 0 eyes |
| Symptomatic | Conjunctival Staining | Inferior-Grade 0 | 30 eyes |
| Symptomatic | Conjunctival Staining | Inferior-Grade 1 | 51 eyes |
| Symptomatic | Conjunctival Staining | Inferior-Grade 2 | 13 eyes |
| Symptomatic | Conjunctival Staining | Inferior-Grade 3 | 2 eyes |
| Symptomatic | Conjunctival Staining | Superior- Grade 0 | 50 eyes |
| Symptomatic | Conjunctival Staining | Superior- Grade 1 | 44 eyes |
| Symptomatic | Conjunctival Staining | Superior- Grade 2 | 2 eyes |
| Symptomatic | Conjunctival Staining | Nasal- Grade 1 | 51 eyes |
Corneal Staining
Corneal staining was assessed for each eye by region (Central, Superior, Inferior, Nasal, Temporal). Corneal staining type was evaluated using the following the scale: Grade 0 = None, Grade 1 = Micropunctate, Grade 2 = Macropunctate, Grade 3 = Coalesced Macropunctate, and Grade 4 = Patch (\>1mm). Corneal staining area was evaluated using the following the scale: Grade 0 = 0% of region covered, Grade 1 = 10% of region covered, Grade 2 = 20% of region covered, Grade 3 = 30% of region covered, Grade 4 = 40% of region covered, Grade 5 = 50% of region covered, Grade 6 = 60% of region covered, Grade 7 = 70% of region covered, Grade 8 = 80% of region covered, Grade 9 = 90% of region covered, and Grade 10 = 100% of region covered. The following scale was used in the grading of corneal staining depth: Grade 0 = None, Grade 0 = Superficial epithelial, Grade 2 = Full epithelial, and Grade 3 = Stromal glow.
Time frame: 4-Week Follow-up
Population: All subjects dispensed a study lens.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Asymptomatic | Corneal Staining | Staining- Area-Nasal-Grade 4 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining Type- Central- Grade 1 | 1 eyes |
| Asymptomatic | Corneal Staining | Staining Type- Central- Grade 2 | 2 eyes |
| Asymptomatic | Corneal Staining | Staining Type- Central- Grade 3 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Inferior - Grade 0 | 48 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Inferior - Grade 1 | 5 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Inferior - Grade 3 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Nasal - Grade 0 | 49 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Nasal - Grade 1 | 4 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Nasal - Grade 2 | 1 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Temporal-Grade 1 | 2 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Temporal-Grade 2 | 1 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Temporal-Grade 3 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining Type- Superior- Grade 0 | 50 eyes |
| Asymptomatic | Corneal Staining | Staining Type- Superior- Grade 3 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Inferior-Grade 0 | 48 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Inferior-Grade 1 | 6 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Inferior-Grade 2 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Nasal-Grade 0 | 49 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Nasal-Grade 1 | 5 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Nasal-Grade 2 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Temporal-Grade 0 | 51 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Temporal-Grade 1 | 3 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Temporal-Grade 2 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Superior-Grade 0 | 50 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Superior-Grade 1 | 4 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Superior-Grade 2 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Central- Grade 2 | 1 eyes |
| Asymptomatic | Corneal Staining | Staining- Area-Nasal-Grade 3 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining- Area-Nasal-Grade 5 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Superior-Grade 2 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Inferior - Grade 2 | 1 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Nasal - Grade 3 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining Type-Temporal-Grade 0 | 51 eyes |
| Asymptomatic | Corneal Staining | Staining Type- Superior- Grade 1 | 4 eyes |
| Asymptomatic | Corneal Staining | Staining Type- Superior- Grade 2 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Central- Grade 0 | 51 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Central- Grade 1 | 1 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Central- Grade 3 | 1 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Central- Grade 4 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Central- Grade 5 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Central- Grade 6 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Inferior- Grade 0 | 48 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Inferior- Grade 1 | 3 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Inferior- Grade 2 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Inferior- Grade 3 | 3 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Inferior- Grade 4 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Inferior- Grade 5 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining- Area- Inferior- Grade 6 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining- Area-Nasal-Grade 0 | 49 eyes |
| Asymptomatic | Corneal Staining | Staining- Area-Nasal-Grade 2 | 1 eyes |
| Asymptomatic | Corneal Staining | Staining- Area-Nasal-Grade 1 | 4 eyes |
| Asymptomatic | Corneal Staining | Staining Type- Central- Grade 0 | 51 eyes |
| Asymptomatic | Corneal Staining | Staining- Area-Nasal-Grade 6 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Temporal-Grade 0 | 51 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Temporal-Grade 1 | 1 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Temporal-Grade 2 | 2 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Temporal-Grade 3 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Temporal-Grade 4 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Temporal-Grade 5 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Temporal-Grade 6 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Superior-Grade 0 | 50 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Superior-Grade 1 | 3 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Superior-Grade 3 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Superior-Grade 4 | 1 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Superior-Grade 5 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Area-Superior-Grade 6 | 0 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Central-Grade 0 | 51 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Central-Grade 1 | 3 eyes |
| Asymptomatic | Corneal Staining | Staining-Depth-Central-Grade 2 | 0 eyes |
| Symptomatic | Corneal Staining | Staining- Area-Nasal-Grade 2 | 1 eyes |
| Symptomatic | Corneal Staining | Staining Type- Central- Grade 0 | 88 eyes |
| Symptomatic | Corneal Staining | Staining Type-Temporal-Grade 0 | 92 eyes |
| Symptomatic | Corneal Staining | Staining Type- Central- Grade 1 | 5 eyes |
| Symptomatic | Corneal Staining | Staining- Area-Nasal-Grade 3 | 0 eyes |
| Symptomatic | Corneal Staining | Staining Type- Central- Grade 2 | 3 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Central-Grade 2 | 0 eyes |
| Symptomatic | Corneal Staining | Staining Type- Central- Grade 3 | 0 eyes |
| Symptomatic | Corneal Staining | Staining Type- Superior- Grade 3 | 0 eyes |
| Symptomatic | Corneal Staining | Staining Type-Inferior - Grade 0 | 75 eyes |
| Symptomatic | Corneal Staining | Staining- Area-Nasal-Grade 4 | 0 eyes |
| Symptomatic | Corneal Staining | Staining Type-Inferior - Grade 1 | 17 eyes |
| Symptomatic | Corneal Staining | Staining- Area-Nasal-Grade 5 | 0 eyes |
| Symptomatic | Corneal Staining | Staining Type-Inferior - Grade 3 | 0 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Central- Grade 2 | 2 eyes |
| Symptomatic | Corneal Staining | Staining Type-Nasal - Grade 0 | 92 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Superior-Grade 0 | 89 eyes |
| Symptomatic | Corneal Staining | Staining Type-Nasal - Grade 1 | 2 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Central- Grade 3 | 1 eyes |
| Symptomatic | Corneal Staining | Staining Type-Nasal - Grade 2 | 2 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Superior-Grade 5 | 0 eyes |
| Symptomatic | Corneal Staining | Staining Type-Temporal-Grade 1 | 2 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Superior-Grade 1 | 4 eyes |
| Symptomatic | Corneal Staining | Staining Type-Temporal-Grade 2 | 2 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Central- Grade 5 | 0 eyes |
| Symptomatic | Corneal Staining | Staining Type-Temporal-Grade 3 | 0 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Temporal-Grade 1 | 2 eyes |
| Symptomatic | Corneal Staining | Staining Type- Superior- Grade 0 | 88 eyes |
| Symptomatic | Corneal Staining | Staining Type- Superior- Grade 1 | 6 eyes |
| Symptomatic | Corneal Staining | Staining Type- Superior- Grade 2 | 2 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Central- Grade 6 | 0 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Superior-Grade 2 | 3 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Inferior-Grade 0 | 77 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Inferior- Grade 0 | 76 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Inferior-Grade 1 | 19 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Temporal-Grade 2 | 2 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Inferior-Grade 2 | 0 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Inferior- Grade 1 | 10 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Nasal-Grade 0 | 93 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Central-Grade 0 | 89 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Nasal-Grade 1 | 3 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Inferior- Grade 2 | 8 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Nasal-Grade 2 | 0 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Temporal-Grade 3 | 0 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Temporal-Grade 0 | 93 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Inferior- Grade 3 | 2 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Temporal-Grade 1 | 3 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Superior-Grade 3 | 0 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Temporal-Grade 2 | 0 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Inferior- Grade 4 | 0 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Superior-Grade 0 | 89 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Temporal-Grade 4 | 0 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Superior-Grade 1 | 7 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Inferior- Grade 5 | 0 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Superior-Grade 2 | 0 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Central- Grade 0 | 89 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Central- Grade 1 | 4 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Superior-Grade 6 | 0 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Central- Grade 4 | 0 eyes |
| Symptomatic | Corneal Staining | Staining- Area-Nasal-Grade 0 | 93 eyes |
| Symptomatic | Corneal Staining | Staining- Area- Inferior- Grade 6 | 0 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Temporal-Grade 5 | 0 eyes |
| Symptomatic | Corneal Staining | Staining- Area-Nasal-Grade 6 | 0 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Temporal-Grade 0 | 92 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Superior-Grade 4 | 0 eyes |
| Symptomatic | Corneal Staining | Staining-Depth-Central-Grade 1 | 7 eyes |
| Symptomatic | Corneal Staining | Staining-Area-Temporal-Grade 6 | 0 eyes |
| Symptomatic | Corneal Staining | Staining Type-Inferior - Grade 2 | 4 eyes |
| Symptomatic | Corneal Staining | Staining- Area-Nasal-Grade 1 | 2 eyes |
| Symptomatic | Corneal Staining | Staining Type-Nasal - Grade 3 | 0 eyes |
Tear Film Lipid Layer Thickness
Tear film lipid layer thickness was measured for each eye using LipiView II. The Review Lipid Images screen provided numerical analysis of the measured lipid layer thickness in nanometers (nm) from 10 (thinnest) to 240 (thickest), with a precision of 1 nm and an accuracy of 10 nm.
Time frame: 4-Week Follow-up
Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Asymptomatic | Tear Film Lipid Layer Thickness | 66.81 nm | Standard Deviation 19.336 |
| Symptomatic | Tear Film Lipid Layer Thickness | 63.00 nm | Standard Deviation 16.208 |
Tear Film Lipid Pattern
Tear film lipid pattern was recorded for each eye using the following categories: None, Open Meshwork, Closed (Tight Meshwork), Flow (Wave), Amorphous, Colors, and Other.
Time frame: 4-Week Follow-up
Population: All subjects that completed all study visits without a major protocol deviation.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Asymptomatic | Tear Film Lipid Pattern | Closed (Tight) | 18 eyes |
| Asymptomatic | Tear Film Lipid Pattern | Amorphous | 11 eyes |
| Asymptomatic | Tear Film Lipid Pattern | Open Meshwork | 6 eyes |
| Asymptomatic | Tear Film Lipid Pattern | Colors | 3 eyes |
| Asymptomatic | Tear Film Lipid Pattern | Flow (Wave) | 14 eyes |
| Asymptomatic | Tear Film Lipid Pattern | Others | 0 eyes |
| Asymptomatic | Tear Film Lipid Pattern | None | 0 eyes |
| Symptomatic | Tear Film Lipid Pattern | Others | 0 eyes |
| Symptomatic | Tear Film Lipid Pattern | None | 0 eyes |
| Symptomatic | Tear Film Lipid Pattern | Open Meshwork | 24 eyes |
| Symptomatic | Tear Film Lipid Pattern | Closed (Tight) | 22 eyes |
| Symptomatic | Tear Film Lipid Pattern | Flow (Wave) | 28 eyes |
| Symptomatic | Tear Film Lipid Pattern | Amorphous | 15 eyes |
| Symptomatic | Tear Film Lipid Pattern | Colors | 5 eyes |
Tear Film Stability
Non-invasive tear break-up time (NIBUT) was measured for each eye to indicate the stability of the tear film. NIBUT is measured as the time interval in seconds after the final blink to the first appearance of distortion in the reflected rings; or to the time that the participant has to blink due to discomfort. Three measurements were taken on each eye. The average NIBUT was reported for each group.
Time frame: 4-Week Follow-up
Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Asymptomatic | Tear Film Stability | 8.03 seconds | Standard Deviation 3.846 |
| Symptomatic | Tear Film Stability | 6.78 seconds | Standard Deviation 4.327 |